TY - JOUR
T1 - Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model
AU - Destache, Christopher J.
AU - Pakiz, Catherine B.
AU - Larsen, Chris
AU - Owens, Heather
AU - Dash, Alekha K.
PY - 2001
Y1 - 2001
N2 - This study was designed to investigate the penetration across the blood-brain barrier of three doses of levofloxacin using a microdialysis probe implanted into the cerebrospinal fluid (CSF) of a rabbit pneumococcal meningitis model. The microdialysis guide cannula was implanted into rabbit subarachnoid space using a stereotaxic frame. After 3 days, 10
4 cfu Streptococcus pneumoniae serotype 3 in 0.3 mL saline was injected via intracisternal puncture and animals were allowed to incubate the organisms for 16-18 h. Groups of animals (n=5) then received 7, 10.5 or 14 mg/kg iv of the drug over 10 min. Plasma samples were obtained via an ear vein 0, 0.25, 0.5, 0.75, 1, 2, 4, 6 and 8 h after the antibiotic infusion. CSF microdialysis effluent samples were collected every 0.5 h for the entire experiment. Plasma and microdialysis effluent samples were analysed by HPLC. AUC
0-8 in plasma and CSF were computed using the trapezoid rule. The elimination half-life in plasma and CSF was calculated using non-linear regression analysis. The unbound peak plasma concentrations for the three doses studied were 3.9, 6.4 and 10.3 mg/L, respectively. There was a significant increase in the plasma AUC
0-8 [29.7 ± 6.3, 49.1 ± 19.1 and 67.6 ± 8.9 mg·h/L (PCSF(0-8) was significantly higher as the dose was increased (7 mg/kg, 15.8 ± 6.6; 10.5 mg/kg, 37.3 ± 7.8; and 14 mg/kg, 46.4 ± 20.9 mg·h/L; P
AB - This study was designed to investigate the penetration across the blood-brain barrier of three doses of levofloxacin using a microdialysis probe implanted into the cerebrospinal fluid (CSF) of a rabbit pneumococcal meningitis model. The microdialysis guide cannula was implanted into rabbit subarachnoid space using a stereotaxic frame. After 3 days, 10
4 cfu Streptococcus pneumoniae serotype 3 in 0.3 mL saline was injected via intracisternal puncture and animals were allowed to incubate the organisms for 16-18 h. Groups of animals (n=5) then received 7, 10.5 or 14 mg/kg iv of the drug over 10 min. Plasma samples were obtained via an ear vein 0, 0.25, 0.5, 0.75, 1, 2, 4, 6 and 8 h after the antibiotic infusion. CSF microdialysis effluent samples were collected every 0.5 h for the entire experiment. Plasma and microdialysis effluent samples were analysed by HPLC. AUC
0-8 in plasma and CSF were computed using the trapezoid rule. The elimination half-life in plasma and CSF was calculated using non-linear regression analysis. The unbound peak plasma concentrations for the three doses studied were 3.9, 6.4 and 10.3 mg/L, respectively. There was a significant increase in the plasma AUC
0-8 [29.7 ± 6.3, 49.1 ± 19.1 and 67.6 ± 8.9 mg·h/L (PCSF(0-8) was significantly higher as the dose was increased (7 mg/kg, 15.8 ± 6.6; 10.5 mg/kg, 37.3 ± 7.8; and 14 mg/kg, 46.4 ± 20.9 mg·h/L; P
UR - http://www.scopus.com/inward/record.url?scp=0035020516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035020516&partnerID=8YFLogxK
U2 - 10.1093/jac/47.5.611
DO - 10.1093/jac/47.5.611
M3 - Article
C2 - 11328772
AN - SCOPUS:0035020516
VL - 47
SP - 611
EP - 615
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
SN - 0305-7453
IS - 5
ER -